BY
fr en
  • Pharmaceutical Solutions
    Pharmaceutical Solutions
    • Pharmaceutical Solutions
    • Small molecules APIs & Intermediates
      • Small molecules APIs & Intermediates
      • Custom Development & Manufacturing
      • Generic APIs
      • Catalog Offer
    • Consumer Health Care
      • Consumer Health Care
      • Acetylsalicylic Acid Offer
      • Salicylic Acid Offer
      • Methyl Salicylate
      • Paracetamol offer
      • Para Amino Phenol
      • Allyl Alcohol Offer
    • Life science Inputs
      • Life science Inputs
      • Hygiene & Disinfectants
      • Diisopropyl Ether (DIPE)
      • Isopropanol (IPA)
      • Isopropyl Acetate (IPAC)
    • Drug Delivery Solutions
      • Drug Delivery Solutions
      • Smart Excipients & Polymers Catalog
      • Custom Lipids
      • Custom GMP Polymers
    • In vitro diagnostic
  • Specialty Ingredients
    Specialty Ingredients
    • Specialty Ingredients
    • Cosmetics
      • Cosmetics
      • Natural Ingredients
      • Advanced Cosmetics
      • Multifunctionals
    • Custom Manufacturing
      • Custom Manufacturing
      • Custom Processing
      • Fine chemicals
      • Catalyst Re-Impregnation
    • Lubricants Additives
      • Lubricants Additives
      • Custom Greases
      • Metal Protection
      • Metalworking
    • Electronics
      • Electronics
      • Micro-Electronics
      • Printed & Organic Electronics
    • Solvents
      • Solvents
      • Oxygenated Solvents
      • Low VOC Solvents
      • Solvent Recovery
    • Upstream platform
      • Upstream platform
      • Phenol & Acetone
      • Upstream Platform Essentials
    • Specialty Chemicals
      • Specialty Chemicals
      • Acetophenone (ACPH)
      • Alpha Methyl Styrene (AMS)
      • Cumene
      • Cumene Hydroperoxide (CHP)
      • Di Iso Propyl Benzene (DIPB)
  • R&D Services
    R&D Services
    • R&D Services
    • Market offering
      • Market offering
      • Pharma early phase development
      • Pharma late phase development
      • Custom ingredients
      • Cosmetics & Personal care
    • Key expertise
      • Key expertise
      • Analytical Excellence
      • Artificial Intelligence
      • Biocatalysis
      • Multi-catalysis
      • Flow Chemistry
      • High-Potency APIs (HPAPIs)
      • Polymers
      • Solid state characterization
    • R&D Excellence centres
      • R&D Excellence centres
      • Seqens’Lab
      • Protéus (Biocatalysis)
      • Boston’Lab (R&D center for Early phase projects)
      • Aramon'Lab (Drug Delivery Polymers)
      • Montreal’ Lab (Electronics)
      • Middlesbrough’Lab (Cosmetics & Fine chem)
    • Business Partners hosting
      • Business Partners hosting
      • A unique ecosystem to accelerate innovative projects
      • Computational predictive toxicology and mechanism of action investigation
      • Toxicology
Locations Products COMMITMENTS Careers
  • About Seqens
    About Seqens
    • SEQENS Group
    • Compliance
    • Group governance
    • Scientific committee
    • Our Partners
  • Material safety data sheet
  • Newsroom
  • Contact
Logo Seqens PNG
Locations Products COMMITMENTS Careers
Logo Seqens PNG
fr en
  • Pharmaceutical Solutions
    Pharmaceutical Solutions
    • Small molecules APIs & Intermediates
      • Custom Development & Manufacturing
      • Generic APIs
      • Catalog Offer
    • Consumer Health Care
      • Acetylsalicylic Acid Offer
      • Salicylic Acid Offer
      • Methyl Salicylate
      • Paracetamol offer
      • Para Amino Phenol
      • Allyl Alcohol Offer
    • Life science Inputs
      • Hygiene & Disinfectants
      • Diisopropyl Ether (DIPE)
      • Isopropanol (IPA)
      • Isopropyl Acetate (IPAC)
    • Drug Delivery Solutions
      • Smart Excipients & Polymers Catalog
      • Custom Lipids
      • Custom GMP Polymers
    • In vitro diagnostic
  • Specialty Ingredients
    Specialty Ingredients
    • Cosmetics
      • Natural Ingredients
      • Advanced Cosmetics
      • Multifunctionals
    • Custom Manufacturing
      • Custom Processing
      • Fine chemicals
      • Catalyst Re-Impregnation
    • Lubricants Additives
      • Custom Greases
      • Metal Protection
      • Metalworking
    • Electronics
      • Micro-Electronics
      • Printed & Organic Electronics
    • Solvents
      • Oxygenated Solvents
      • Low VOC Solvents
      • Solvent Recovery
    • Upstream platform
      • Phenol & Acetone
      • Upstream Platform Essentials
    • Specialty Chemicals
      • Acetophenone (ACPH)
      • Alpha Methyl Styrene (AMS)
      • Cumene
      • Cumene Hydroperoxide (CHP)
      • Di Iso Propyl Benzene (DIPB)
  • R&D Services
    R&D Services
    • Market offering
      • Pharma early phase development
      • Pharma late phase development
      • Custom ingredients
      • Cosmetics & Personal care
    • Key expertise
      • Analytical Excellence
      • Artificial Intelligence
      • Biocatalysis
      • Multi-catalysis
      • Flow Chemistry
      • High-Potency APIs (HPAPIs)
      • Polymers
      • Solid state characterization
    • R&D Excellence centres
      • Seqens’Lab
      • Protéus (Biocatalysis)
      • Boston’Lab (R&D center for Early phase projects)
      • Aramon'Lab (Drug Delivery Polymers)
      • Montreal’ Lab (Electronics)
      • Middlesbrough’Lab (Cosmetics & Fine chem)
    • Business Partners hosting
      • A unique ecosystem to accelerate innovative projects
      • Computational predictive toxicology and mechanism of action investigation
      • Toxicology
Top of page
  • About Seqens
  • Material safety data sheet
  • Newsroom
  • Contact

SEQENSgroup

  • SEQENS Group
  • Compliance
  • Group governance
  • Scientific committee
  • Our Partners
Share

Newsroom

Home Newsroom
General / Press Release

Change in SEQENS’ shareholding structure

17th december 2021

SEQENS is now stronger, more focused and positioned as one of the world’s leading players in pharmaceutical solutions and specialty ingredients 3 new…

Read more
General 05th september 2022

SEQENS Turku Plant (Finland) reaches 100% Renewable Energy and zero direct carbon emissions

This achievement reflects SEQENS strong commitment to reduce its environmental and carbon footprint in line with the Group ESG Program. SEQENS, an integrated…

Read more
Events 28th march 2022

DCAT 2022: a success for Seqens group

From March 21 to 24, 2022, a delegation representing all of the group’s pharmaceutical activities took part in the DCAT event in New York.

Read more
Press Release 21st march 2022

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

Investment Signals Major Commitment to U.S. Market and Builds on Merger with Contract Development and Manufacturing Organization Wavelength Pharmaceuticals. investment in Devens SEQENS,…

Read more
General 09th march 2022

Meeting with Virginie Tarlet for the International Women’s Day

For the International Women’s day, SEQENS highlights the career path of inspiring women working within the group. Meet Virginie Tarlet Roussillon Lab manager. What is…

Read more
General 08th march 2022

Meeting with Aïna Queiroz for the International Women’s Day

For the International Women’s day, SEQENS highlights the career path of inspiring women working within the group. Meet Aïna Queiroz, Head of innovation and scientific…

Read more
General 08th march 2022

Meeting with Yael Gofni for the International Women’s Day

For the International Women’s day, SEQENS highlights the career path of inspiring women working within the group. Meet Yael Gofni analytical…

Read more
General 25th january 2022

Update on isopropanol plant expansion

Seqens Solvents & Phenol Specialties (SPS) is proud to confirm that its isopropanol (IPA) plant capacity expansion, originally announced in Q2 2020 and…

Read more
General / Press Release 17th december 2021

Change in SEQENS’ shareholding structure

SEQENS is now stronger, more focused and positioned as one of the world’s leading players in pharmaceutical solutions and specialty ingredients 3 new…

Read more
General / Press Release 17th december 2021

SK Capital becomes the new majority shareholder of Seqens – Q&A

As announced on the 26th of August 2021, Eurazeo has finalized on Decembre 16th the sale of its stake in SEQENS to funds advised…

Read more
General 16th december 2021

Seqens becomes a partner of the RoLA-FLEX project

RoLA-FLEX is an industry-focused project that provides innovative solutions to the challenge associated with th performance and lifetime of Organic…

Read more

Join theSeqens teams!

Find out more

A question? A need?Contact us

Contact us

Follow the seqens evolution onsocial medias

  • Home
  • Newsroom
  • Press / Media
  • GTC
  • Personal data & cookies
  • Legal information

DISCOVER OUR NEWS

Learn more